Pure Global
NCT06153069

Subclinical TB With Innovative Modified Short-course Regimens

Clinical Efficacy of a Short-course Regimen for Subclinical Tuberculosis in China
Huashan Hospital·Phase 4·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Tuberculosis
Drug/Device/Intervention
Short-course regimen
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Huashan Hospital
Location
Shanghai,Hangzhou, China
Timeline & enrollment
Phase
Phase 4
Start date
Nov 01, 2023
End date
Nov 01, 2027
Enrollment
556 participants
Primary outcome

Treatment success rate of the short-course regimen

Summary

This study is a randomized controlled trial among subclinical tuberculosis patients aiming to
 assess whether the standard treatment duration can be shortened to 17 weeks or even 8 weeks
 without changing the current anti-tuberculosis drugs or dosages.

ICD-10 classifications
TuberculosisLatent tuberculosisTuberculosis of other organsCongenital tuberculosisSequelae of tuberculosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06153069
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06153069 through Pure Global AI's free database. This Phase 4 trial is sponsored by Huashan Hospital and is currently Recruitment Completed. The study focuses on Tuberculosis. Target enrollment is 556 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.